Thomas Leroy

@jryckman3 @IJROBP @KonradStawiski @piet_ost @OrthancServer

This is awesome, thanks for sharing! Would love an open-source tool to let PACS properly display RT DICOM information as well. Our issue with our PACS is that it can store RT DICOM information, but it cannot display it, so we are trying to get creative with MIM with "burned-in" images. On a related note to one aspect of the project you shared, we built open-source software to harmonize the RT Structure Set nomenclature. It’s got consensus English, French & Spanish translations (sorry, no Polish yet!) and it is endorsed by the @AAPM_TG263U1 WG. #OncTwitter #RadOnc redjournal.org/article/S0360-… @IJROBP @_BrianAnderson_

1/ A very real problem in modern radiation oncology: The treatment plan is often highly detailed. The hospital record is often not. The TPS knows exactly what we treated, where we treated it, and to what dose. But much of that context never leaves the bunker. #ESTRO26 #RadOnc

@jryckman3 @IJROBP @KonradStawiski @piet_ost Orthanc pacs and Ohif viewer can do that and it’s open-source

@JLMelenchon Faut arrêter de raconter n'importe quoi. Laissez la santé et le cancer aux professionnels.

#YAU_RenalCancerSpotlight No. 8 📌 Editorial comment: current evidence comparing SBRT and ablative therapies for localized RCC, highlighting strengths, limitations & unmet clinical needs pubmed.ncbi.nlm.nih.gov/41410671/ 📖 Available on @MUN_journal @TheLancetOncol @OncoAlert

@PBlanchardMD The final publication of our STEREOPOSTOP trial has just been published ! @PBlanchardMD @gortec @YG_TAO jamanetwork.com/journals/jaman…

When the New England Journal of Medicine published the SUPREMO trial this week, social media lit up with headlines like: “Radiotherapy after mastectomy can be avoided, study finds” It’s an appealing headline, but dangerously incomplete. brianlawenda.substack.com/p/why-the-supr…

@Aiden_Tech_Ai DS

DeepSeek is a crypto money printer 🚨 I wrote a Bot, that's made me $35K from $100 last night. This isn’t clickbait—just an AI Trading Bot powered by DeepSeek. FREE for 24 hrs then deleted! Simply, 1. RT 2. Like 3. Reply "DS" and Follow me and I'll send you a DM.

Does the addition of radiofrequency ablation/vertebral augmentation to radiotherapy improve pain outcomes for painful spine mets? NO according to this Phase IIR academic.oup.com/neuro-oncology…

Here's another new ARREST2 case - 10 lung lesions (also liver lesions treated by @TimkWin not shown). Most of these will receive 20 Gy in 1 fraction, the ones adjacent to important structures get 35/5.

Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer Congrats to the PCS IX team! author link at @TheLancetOncol: authors.elsevier.com/a/1liJQ5EIIgTS…

A recent randomized study was published for patients with grade 0-2 knee osteoarthritis. It compared drug therapy alone vs drug therapy + low dose radiation (LDRT). It was a 3 year follow-up. LDRT did better in every metric analyzed. ❇️ Fig. Below shows dynamics of the physical component of the quality of life of patients with knee OA depending on the treatment method: ❇️glucosamine/chondroitin alone vs glucosamine/chondroitin in combination with LDRT: a) PF - physical functioning; b) RP -role functioning; c) BP - physical pain; d) GH - general perception of health Ref: researchgate.net/publication/36…

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial) 💥OS after active surveillance was not inferior to standard surgery at 2 years thelancet.com/journals/lanon…

J'ai demandé à #Boiron une source scientifique prouvant l'efficacité de l'homéopathie. Très gentiment ils ont obtempéré. hri-research.org/wp-content/upl… Nous allons ici démonter point par point tout ça.

🚨Reduced-Volume RT in NPC: Breakthrough or Bold Move? @OncoAlert 🎯 Aim: ➖Test if reduced-volume☢️post-induction chemo (IC) is noninferior to conventional ☢️ in nasopharyngeal carcinoma (NPC) for locoregional control, toxicity, and QoL 🏥 Methods: ➖Ph3, multicenter, RCT(n=445) ➖Post-IC group: GTV based on post-IC MRI (70 Gy); pre-IC group: pre-IC volume (70 Gy) ➖IMRT, 60-62 Gy to high-risk CTV, 54-56 Gy to low-risk CTV, 30-33fx ➖Cisplatin concurrent 📊 Results: ➖3-yr LRFS: 91.5% (post-IC) vs 91.2% (pre-IC) ➖⬇️ grade 3-4 tox (mucositis: 19.8% vs 34.1%; otitis: 9.5% vs 20.9%) and ⬆️ QoL in post-IC Clinically actionable: ➖⬇️toxicity, 🟰 efficacy❗️

Our incredible GI leaders paving the path for EBRT in HCC. Published in @LancetGastroHep “Compelling new randomised controlled trial results support that future hepatocellular carcinoma guidelines should include EBRT”. See figure. @StephDudzinski, you’re a superstar!

🔥 SBRT for HCC - ready for prime time 🔥 ❓ NRG Oncology/RTOG 1112 ❓ Recent clinical trials ❓ Guideline perspective ❓ Patient selection Virtual Grand Rounds in Radiation Oncology Presented by Prof @ldawsonmd Wed March 5th 17:00 – 17:45 CET 👇 usz.ch/en/events/virt…

A major advance in laser-proton devices has been reported. It can produce energies up to 6MeV at FLASH dose rates. The beams are collimated by the plasma produced by the beam itself. 'Stable laser-acceleration of high-flux proton beams with plasma collimation' PMID: 39856070

⚡️PCa Oral Abstract Session⚡️ RT vs RP in HR-PCa: Emulated randomized comparison w/ IPD from 2 Ph III RCTs @Soum_Roy_RadOnc @urotoday #GU25 📍n=1,290 ; RT n=557, RP n=733 📍RT vs RP, 8-yr DM: 16% vs 23%; sHR 0.56, 95%CI 0.38-0.81 📍RT + LT-ADT vs Doce + ADT + RP, 8-yr DM: 18% vs 21%; sHR 0.84, 95%CI 0.51-1.37 📍RT vs RP, 8-yr Risk of death w/o DM: HR 2.14, 95%CI 1.12-4.19

Ab#22 @ASCO #GU25 by @niazi_Dr7👉bit.ly/4hMu4KE👉Randomized ph2 study of MDT in oligometastatic CRPC #prostatecancer👉addition of SBRT to SOC doubled the median rPFS (& delayed time to next Rx)👇#ScottTyldesley @OncoAlert @urotoday @PCF_Science

📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc